ES2637024T3 - Composición farmacéutica para el tratamiento de enfermedades inflamatorias mediadas por MCP-1 - Google Patents
Composición farmacéutica para el tratamiento de enfermedades inflamatorias mediadas por MCP-1 Download PDFInfo
- Publication number
- ES2637024T3 ES2637024T3 ES10747897.6T ES10747897T ES2637024T3 ES 2637024 T3 ES2637024 T3 ES 2637024T3 ES 10747897 T ES10747897 T ES 10747897T ES 2637024 T3 ES2637024 T3 ES 2637024T3
- Authority
- ES
- Spain
- Prior art keywords
- captopril
- group
- pharmaceutical composition
- arb
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 102100021943 C-C motif chemokine 2 Human genes 0.000 title 1
- 101710155857 C-C motif chemokine 2 Proteins 0.000 title 1
- 208000027866 inflammatory disease Diseases 0.000 title 1
- 230000001404 mediated effect Effects 0.000 title 1
- -1 benzoyl-captopril Chemical compound 0.000 abstract 10
- QIJLJZOGPPQCOG-NFAWXSAZSA-N (2s)-1-[(2s)-3-[(2r)-2-(cyclohexanecarbonylamino)propanoyl]sulfanyl-2-methylpropanoyl]pyrrolidine-2-carboxylic acid Chemical compound N([C@H](C)C(=O)SC[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)C(=O)C1CCCCC1 QIJLJZOGPPQCOG-NFAWXSAZSA-N 0.000 abstract 2
- 239000005541 ACE inhibitor Substances 0.000 abstract 2
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 abstract 2
- VXFJYXUZANRPDJ-WTNASJBWSA-N Trandopril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@H]2CCCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 VXFJYXUZANRPDJ-WTNASJBWSA-N 0.000 abstract 2
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 abstract 2
- 229960000830 captopril Drugs 0.000 abstract 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 2
- RMMXLENWKUUMAY-UHFFFAOYSA-N telmisartan Chemical compound CCCC1=NC2=C(C)C=C(C=3N(C4=CC=CC=C4N=3)C)C=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O RMMXLENWKUUMAY-UHFFFAOYSA-N 0.000 abstract 2
- HMJIYCCIJYRONP-UHFFFAOYSA-N (+-)-Isradipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)C1C1=CC=CC2=NON=C12 HMJIYCCIJYRONP-UHFFFAOYSA-N 0.000 abstract 1
- NVXFXLSOGLFXKQ-JMSVASOKSA-N (2s)-1-[(2r,4r)-5-ethoxy-2,4-dimethyl-5-oxopentanoyl]-2,3-dihydroindole-2-carboxylic acid Chemical compound C1=CC=C2N(C(=O)[C@H](C)C[C@@H](C)C(=O)OCC)[C@H](C(O)=O)CC2=C1 NVXFXLSOGLFXKQ-JMSVASOKSA-N 0.000 abstract 1
- OMGPCTGQLHHVDU-SSXGPBTGSA-N (2s)-3-[(2s)-2-[[(2s)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-3-azabicyclo[2.2.2]octane-2-carboxylic acid Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C2CCC1CC2)C(O)=O)CC1=CC=CC=C1 OMGPCTGQLHHVDU-SSXGPBTGSA-N 0.000 abstract 1
- BIDNLKIUORFRQP-XYGFDPSESA-N (2s,4s)-4-cyclohexyl-1-[2-[[(1s)-2-methyl-1-propanoyloxypropoxy]-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid Chemical compound C([P@@](=O)(O[C@H](OC(=O)CC)C(C)C)CC(=O)N1[C@@H](C[C@H](C1)C1CCCCC1)C(O)=O)CCCC1=CC=CC=C1 BIDNLKIUORFRQP-XYGFDPSESA-N 0.000 abstract 1
- PVHUJELLJLJGLN-INIZCTEOSA-N (S)-nitrendipine Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC([N+]([O-])=O)=C1 PVHUJELLJLJGLN-INIZCTEOSA-N 0.000 abstract 1
- FAKRSMQSSFJEIM-BQBZGAKWSA-N 1-(3-mercapto-2-methyl-propionyl)-pyrrolidine-2-carboxylic acid Chemical compound SC[C@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-BQBZGAKWSA-N 0.000 abstract 1
- JQSAYKKFZOSZGJ-UHFFFAOYSA-N 1-[bis(4-fluorophenyl)methyl]-4-[(2,3,4-trimethoxyphenyl)methyl]piperazine Chemical compound COC1=C(OC)C(OC)=CC=C1CN1CCN(C(C=2C=CC(F)=CC=2)C=2C=CC(F)=CC=2)CC1 JQSAYKKFZOSZGJ-UHFFFAOYSA-N 0.000 abstract 1
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 abstract 1
- MTHORRSSURHQPZ-UHFFFAOYSA-N 2-[(1-benzylindazol-3-yl)methoxy]-2-methylpropanoic acid Chemical compound C12=CC=CC=C2C(COC(C)(C)C(O)=O)=NN1CC1=CC=CC=C1 MTHORRSSURHQPZ-UHFFFAOYSA-N 0.000 abstract 1
- ZBIAKUMOEKILTF-UHFFFAOYSA-N 2-[4-[4,4-bis(4-fluorophenyl)butyl]-1-piperazinyl]-N-(2,6-dimethylphenyl)acetamide Chemical compound CC1=CC=CC(C)=C1NC(=O)CN1CCN(CCCC(C=2C=CC(F)=CC=2)C=2C=CC(F)=CC=2)CC1 ZBIAKUMOEKILTF-UHFFFAOYSA-N 0.000 abstract 1
- NSVFSAJIGAJDMR-UHFFFAOYSA-N 2-[benzyl(phenyl)amino]ethyl 5-(5,5-dimethyl-2-oxido-1,3,2-dioxaphosphinan-2-yl)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3-carboxylate Chemical compound CC=1NC(C)=C(C(=O)OCCN(CC=2C=CC=CC=2)C=2C=CC=CC=2)C(C=2C=C(C=CC=2)[N+]([O-])=O)C=1P1(=O)OCC(C)(C)CO1 NSVFSAJIGAJDMR-UHFFFAOYSA-N 0.000 abstract 1
- UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 abstract 1
- ZGRIPYHIFXGCHR-UHFFFAOYSA-N 3-o-[2-[(4-fluorophenyl)methyl-methylamino]ethyl] 5-o-propan-2-yl 4-(1,3-benzodioxol-4-yl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate Chemical group C=1C=CC=2OCOC=2C=1C1C(C(=O)OC(C)C)=C(C)NC(C)=C1C(=O)OCCN(C)CC1=CC=C(F)C=C1 ZGRIPYHIFXGCHR-UHFFFAOYSA-N 0.000 abstract 1
- RZTAMFZIAATZDJ-HNNXBMFYSA-N 5-o-ethyl 3-o-methyl (4s)-4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC(Cl)=C1Cl RZTAMFZIAATZDJ-HNNXBMFYSA-N 0.000 abstract 1
- FHHHOYXPRDYHEZ-COXVUDFISA-N Alacepril Chemical group CC(=O)SC[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 FHHHOYXPRDYHEZ-COXVUDFISA-N 0.000 abstract 1
- 239000002083 C09CA01 - Losartan Substances 0.000 abstract 1
- 239000004072 C09CA03 - Valsartan Substances 0.000 abstract 1
- 239000002947 C09CA04 - Irbesartan Substances 0.000 abstract 1
- 239000002053 C09CA06 - Candesartan Substances 0.000 abstract 1
- 239000005537 C09CA07 - Telmisartan Substances 0.000 abstract 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 abstract 1
- 229940127291 Calcium channel antagonist Drugs 0.000 abstract 1
- NEEBNBLVYKFVTK-VGMNWLOBSA-N Captopril-cysteine disulfide Chemical compound OC(=O)[C@@H](N)CSSC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O NEEBNBLVYKFVTK-VGMNWLOBSA-N 0.000 abstract 1
- IFYLTXNCFVRALQ-OALUTQOASA-N Ceronapril Chemical compound O([C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)P(O)(=O)CCCCC1=CC=CC=C1 IFYLTXNCFVRALQ-OALUTQOASA-N 0.000 abstract 1
- 229940123715 Chloride channel antagonist Drugs 0.000 abstract 1
- KJEBULYHNRNJTE-DHZHZOJOSA-N Cinalong Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC\C=C\C=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 KJEBULYHNRNJTE-DHZHZOJOSA-N 0.000 abstract 1
- 108010061435 Enalapril Proteins 0.000 abstract 1
- 108010066671 Enalaprilat Proteins 0.000 abstract 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 abstract 1
- 208000001953 Hypotension Diseases 0.000 abstract 1
- 108010007859 Lisinopril Proteins 0.000 abstract 1
- HBNPJJILLOYFJU-VMPREFPWSA-N Mibefradil Chemical compound C1CC2=CC(F)=CC=C2[C@H](C(C)C)[C@@]1(OC(=O)COC)CCN(C)CCCC1=NC2=CC=CC=C2N1 HBNPJJILLOYFJU-VMPREFPWSA-N 0.000 abstract 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 abstract 1
- ZBBHBTPTTSWHBA-UHFFFAOYSA-N Nicardipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)CC=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZBBHBTPTTSWHBA-UHFFFAOYSA-N 0.000 abstract 1
- FAIIFDPAEUKBEP-UHFFFAOYSA-N Nilvadipine Chemical compound COC(=O)C1=C(C#N)NC(C)=C(C(=O)OC(C)C)C1C1=CC=CC([N+]([O-])=O)=C1 FAIIFDPAEUKBEP-UHFFFAOYSA-N 0.000 abstract 1
- 239000005480 Olmesartan Substances 0.000 abstract 1
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 abstract 1
- IFFPICMESYHZPQ-UHFFFAOYSA-N Prenylamine Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)CCNC(C)CC1=CC=CC=C1 IFFPICMESYHZPQ-UHFFFAOYSA-N 0.000 abstract 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 abstract 1
- AJLFOPYRIVGYMJ-UHFFFAOYSA-N SJ000287055 Natural products C12C(OC(=O)C(C)CC)CCC=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 AJLFOPYRIVGYMJ-UHFFFAOYSA-N 0.000 abstract 1
- GYKFWCDBQAFCLJ-RTWAWAEBSA-N [(2s,3s)-8-chloro-5-[2-(dimethylamino)ethyl]-2-(4-methoxyphenyl)-4-oxo-2,3-dihydro-1,5-benzothiazepin-3-yl] acetate Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=C(Cl)C=C2S1 GYKFWCDBQAFCLJ-RTWAWAEBSA-N 0.000 abstract 1
- 229950007884 alacepril Drugs 0.000 abstract 1
- 229960000528 amlodipine Drugs 0.000 abstract 1
- HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 abstract 1
- 229940125364 angiotensin receptor blocker Drugs 0.000 abstract 1
- 229960002992 barnidipine Drugs 0.000 abstract 1
- VXMOONUMYLCFJD-DHLKQENFSA-N barnidipine Chemical compound C1([C@@H]2C(=C(C)NC(C)=C2C(=O)OC)C(=O)O[C@@H]2CN(CC=3C=CC=CC=3)CC2)=CC=CC([N+]([O-])=O)=C1 VXMOONUMYLCFJD-DHLKQENFSA-N 0.000 abstract 1
- FYJJXENSONZJRG-UHFFFAOYSA-N bencyclane Chemical compound C=1C=CC=CC=1CC1(OCCCN(C)C)CCCCCC1 FYJJXENSONZJRG-UHFFFAOYSA-N 0.000 abstract 1
- 229960000945 bencyclane Drugs 0.000 abstract 1
- 229960004916 benidipine Drugs 0.000 abstract 1
- QZVNQOLPLYWLHQ-ZEQKJWHPSA-N benidipine Chemical compound C1([C@H]2C(=C(C)NC(C)=C2C(=O)OC)C(=O)O[C@H]2CN(CC=3C=CC=CC=3)CCC2)=CC=CC([N+]([O-])=O)=C1 QZVNQOLPLYWLHQ-ZEQKJWHPSA-N 0.000 abstract 1
- UIEATEWHFDRYRU-UHFFFAOYSA-N bepridil Chemical compound C1CCCN1C(COCC(C)C)CN(C=1C=CC=CC=1)CC1=CC=CC=C1 UIEATEWHFDRYRU-UHFFFAOYSA-N 0.000 abstract 1
- 229960003665 bepridil Drugs 0.000 abstract 1
- 239000011575 calcium Substances 0.000 abstract 1
- 229910052791 calcium Inorganic materials 0.000 abstract 1
- 229960000932 candesartan Drugs 0.000 abstract 1
- SGZAIDDFHDDFJU-UHFFFAOYSA-N candesartan Chemical compound CCOC1=NC2=CC=CC(C(O)=O)=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SGZAIDDFHDDFJU-UHFFFAOYSA-N 0.000 abstract 1
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 abstract 1
- 229950005749 ceronapril Drugs 0.000 abstract 1
- 239000003638 chemical reducing agent Substances 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 235000012000 cholesterol Nutrition 0.000 abstract 1
- 229950006523 cilexetil Drugs 0.000 abstract 1
- 229960003020 cilnidipine Drugs 0.000 abstract 1
- 229950000308 clentiazem Drugs 0.000 abstract 1
- VTDCYOLLYVAJSY-UHFFFAOYSA-N cyclohexyl propan-2-yl carbonate Chemical compound CC(C)OC(=O)OC1CCCCC1 VTDCYOLLYVAJSY-UHFFFAOYSA-N 0.000 abstract 1
- HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 abstract 1
- 229960004166 diltiazem Drugs 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 229950003102 efonidipine Drugs 0.000 abstract 1
- 229960000873 enalapril Drugs 0.000 abstract 1
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 abstract 1
- 229960002680 enalaprilat Drugs 0.000 abstract 1
- LZFZMUMEGBBDTC-QEJZJMRPSA-N enalaprilat (anhydrous) Chemical compound C([C@H](N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 LZFZMUMEGBBDTC-QEJZJMRPSA-N 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 229960004351 etafenone Drugs 0.000 abstract 1
- OEGDFSLNGABBKJ-UHFFFAOYSA-N etafenone Chemical compound CCN(CC)CCOC1=CC=CC=C1C(=O)CCC1=CC=CC=C1 OEGDFSLNGABBKJ-UHFFFAOYSA-N 0.000 abstract 1
- 229960003580 felodipine Drugs 0.000 abstract 1
- 229960000326 flunarizine Drugs 0.000 abstract 1
- SMANXXCATUTDDT-QPJJXVBHSA-N flunarizine Chemical compound C1=CC(F)=CC=C1C(C=1C=CC(F)=CC=1)N1CCN(C\C=C\C=2C=CC=CC=2)CC1 SMANXXCATUTDDT-QPJJXVBHSA-N 0.000 abstract 1
- 229960002490 fosinopril Drugs 0.000 abstract 1
- 229960001880 fosinopril sodium Drugs 0.000 abstract 1
- 229960003180 glutathione Drugs 0.000 abstract 1
- 208000021822 hypotensive Diseases 0.000 abstract 1
- 230000001077 hypotensive effect Effects 0.000 abstract 1
- 229950009810 indolapril Drugs 0.000 abstract 1
- 229960002198 irbesartan Drugs 0.000 abstract 1
- YCPOHTHPUREGFM-UHFFFAOYSA-N irbesartan Chemical compound O=C1N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C=2[N]N=NN=2)C(CCCC)=NC21CCCC2 YCPOHTHPUREGFM-UHFFFAOYSA-N 0.000 abstract 1
- 229960004427 isradipine Drugs 0.000 abstract 1
- 229960004340 lacidipine Drugs 0.000 abstract 1
- GKQPCPXONLDCMU-CCEZHUSRSA-N lacidipine Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OCC)C1C1=CC=CC=C1\C=C\C(=O)OC(C)(C)C GKQPCPXONLDCMU-CCEZHUSRSA-N 0.000 abstract 1
- 229960004294 lercanidipine Drugs 0.000 abstract 1
- ZDXUKAKRHYTAKV-UHFFFAOYSA-N lercanidipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)(C)CN(C)CCC(C=2C=CC=CC=2)C=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZDXUKAKRHYTAKV-UHFFFAOYSA-N 0.000 abstract 1
- 229960001941 lidoflazine Drugs 0.000 abstract 1
- 229960002394 lisinopril Drugs 0.000 abstract 1
- RLAWWYSOJDYHDC-BZSNNMDCSA-N lisinopril Chemical compound C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 RLAWWYSOJDYHDC-BZSNNMDCSA-N 0.000 abstract 1
- 229950007692 lomerizine Drugs 0.000 abstract 1
- 229960004773 losartan Drugs 0.000 abstract 1
- KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 abstract 1
- 229960004844 lovastatin Drugs 0.000 abstract 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 abstract 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 abstract 1
- 229960003963 manidipine Drugs 0.000 abstract 1
- ANEBWFXPVPTEET-UHFFFAOYSA-N manidipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN2CCN(CC2)C(C=2C=CC=CC=2)C=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ANEBWFXPVPTEET-UHFFFAOYSA-N 0.000 abstract 1
- VKQFCGNPDRICFG-UHFFFAOYSA-N methyl 2-methylpropyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCC(C)C)C1C1=CC=CC=C1[N+]([O-])=O VKQFCGNPDRICFG-UHFFFAOYSA-N 0.000 abstract 1
- AJLFOPYRIVGYMJ-INTXDZFKSA-N mevastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=CCC[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 AJLFOPYRIVGYMJ-INTXDZFKSA-N 0.000 abstract 1
- 229950009116 mevastatin Drugs 0.000 abstract 1
- BOZILQFLQYBIIY-UHFFFAOYSA-N mevastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CCC=C21 BOZILQFLQYBIIY-UHFFFAOYSA-N 0.000 abstract 1
- 229960004438 mibefradil Drugs 0.000 abstract 1
- 229950006549 moveltipril Drugs 0.000 abstract 1
- 229960001783 nicardipine Drugs 0.000 abstract 1
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 abstract 1
- 229960001597 nifedipine Drugs 0.000 abstract 1
- 229960005366 nilvadipine Drugs 0.000 abstract 1
- 229960000715 nimodipine Drugs 0.000 abstract 1
- 229960000227 nisoldipine Drugs 0.000 abstract 1
- 229960005425 nitrendipine Drugs 0.000 abstract 1
- 229960005117 olmesartan Drugs 0.000 abstract 1
- VTRAEEWXHOVJFV-UHFFFAOYSA-N olmesartan Chemical compound CCCC1=NC(C(C)(C)O)=C(C(O)=O)N1CC1=CC=C(C=2C(=CC=CC=2)C=2NN=NN=2)C=C1 VTRAEEWXHOVJFV-UHFFFAOYSA-N 0.000 abstract 1
- 229950008492 pentopril Drugs 0.000 abstract 1
- 229960002582 perindopril Drugs 0.000 abstract 1
- IPVQLZZIHOAWMC-QXKUPLGCSA-N perindopril Chemical compound C1CCC[C@H]2C[C@@H](C(O)=O)N(C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC)[C@H]21 IPVQLZZIHOAWMC-QXKUPLGCSA-N 0.000 abstract 1
- 229960005226 perindoprilat Drugs 0.000 abstract 1
- ODAIHABQVKJNIY-PEDHHIEDSA-N perindoprilat Chemical compound C1CCC[C@H]2C[C@@H](C(O)=O)N(C(=O)[C@H](C)N[C@@H](CCC)C(O)=O)[C@H]21 ODAIHABQVKJNIY-PEDHHIEDSA-N 0.000 abstract 1
- 229960002965 pravastatin Drugs 0.000 abstract 1
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 abstract 1
- 229960001989 prenylamine Drugs 0.000 abstract 1
- 229960001455 quinapril Drugs 0.000 abstract 1
- JSDRRTOADPPCHY-HSQYWUDLSA-N quinapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC=CC=C2C1)C(O)=O)CC1=CC=CC=C1 JSDRRTOADPPCHY-HSQYWUDLSA-N 0.000 abstract 1
- 229960003042 quinapril hydrochloride Drugs 0.000 abstract 1
- IBBLRJGOOANPTQ-JKVLGAQCSA-N quinapril hydrochloride Chemical compound Cl.C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC=CC=C2C1)C(O)=O)CC1=CC=CC=C1 IBBLRJGOOANPTQ-JKVLGAQCSA-N 0.000 abstract 1
- 229960001007 quinaprilat Drugs 0.000 abstract 1
- FLSLEGPOVLMJMN-YSSFQJQWSA-N quinaprilat Chemical compound C([C@H](N[C@@H](C)C(=O)N1[C@@H](CC2=CC=CC=C2C1)C(O)=O)C(O)=O)CC1=CC=CC=C1 FLSLEGPOVLMJMN-YSSFQJQWSA-N 0.000 abstract 1
- 229960003401 ramipril Drugs 0.000 abstract 1
- HDACQVRGBOVJII-JBDAPHQKSA-N ramipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@@H]2CCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 HDACQVRGBOVJII-JBDAPHQKSA-N 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229960002855 simvastatin Drugs 0.000 abstract 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 abstract 1
- TVTJZMHAIQQZTL-WATAJHSMSA-M sodium;(2s,4s)-4-cyclohexyl-1-[2-[[(1s)-2-methyl-1-propanoyloxypropoxy]-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylate Chemical compound [Na+].C([P@@](=O)(O[C@H](OC(=O)CC)C(C)C)CC(=O)N1[C@@H](C[C@H](C1)C1CCCCC1)C([O-])=O)CCCC1=CC=CC=C1 TVTJZMHAIQQZTL-WATAJHSMSA-M 0.000 abstract 1
- 229960002909 spirapril Drugs 0.000 abstract 1
- HRWCVUIFMSZDJS-SZMVWBNQSA-N spirapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2(C1)SCCS2)C(O)=O)CC1=CC=CC=C1 HRWCVUIFMSZDJS-SZMVWBNQSA-N 0.000 abstract 1
- 108700035424 spirapril Proteins 0.000 abstract 1
- 229960005187 telmisartan Drugs 0.000 abstract 1
- UISARWKNNNHPGI-UHFFFAOYSA-N terodiline Chemical compound C=1C=CC=CC=1C(CC(C)NC(C)(C)C)C1=CC=CC=C1 UISARWKNNNHPGI-UHFFFAOYSA-N 0.000 abstract 1
- 229960005383 terodiline Drugs 0.000 abstract 1
- 229960002051 trandolapril Drugs 0.000 abstract 1
- 229960004699 valsartan Drugs 0.000 abstract 1
- SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 abstract 1
- 229960001722 verapamil Drugs 0.000 abstract 1
- 229950009999 zabicipril Drugs 0.000 abstract 1
- 229960002769 zofenopril Drugs 0.000 abstract 1
- IAIDUHCBNLFXEF-MNEFBYGVSA-N zofenopril Chemical compound C([C@@H](C)C(=O)N1[C@@H](C[C@@H](C1)SC=1C=CC=CC=1)C(O)=O)SC(=O)C1=CC=CC=C1 IAIDUHCBNLFXEF-MNEFBYGVSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Child & Adolescent Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Composición farmacéutica, que comprende: (a) el ácido 2-((1-bencil-3-indazolil)metoxi)-2-metilpropiónico que presenta la fórmula estructural siguiente: (b) por lo menos uno de entre (i) un agente hipotensor seleccionado de entre unos inhibidores de ACE, ARB y CCB, y/o (ii) un agente reductor del colesterol seleccionado de entre unos derivados de estatina, o cualquier sal farmacéuticamente aceptable y éster del mismo, y (c) por lo menos un vehículo farmacéuticamente aceptable, en la que dicho inhibidor de ACE se selecciona de entre el grupo que consiste en alacepril, altiopril calcio, benzoil-captopril, captopril, captopril-cisteína, captopril-glutatión, ceronapril, converstatina, enalapril, enalaprilato, epicaptopril, fosinopril, fosinopril sodio, fosinoprilato, hemorfina-4, indolapril, indolaprilato, lisinopril, moveltipril, pentopril, perindopril, perindoprilato, quinapril, clorhidrato de quinapril, quinaprilato, ramipril, ramiprilato, espirapril, clorhidrato de espirapril, espiraprilato, trandolapril, trandolaprilato, zabicipril, zabiciprilato, zofenopril, zofenoprilato, dicho ARB se selecciona de entre el grupo que consiste en candesartán, cilexetilo, irbesartán, losartán, olmesartán, telmisartán, valsartán y pratosartán, dicho CCB se selecciona de entre el grupo que consiste en amlodipino, aranidipino, barnidipino, benidipino, cilnidipino, efonidipino, elgodipino, felodipino, isradipino, lacidipino, lercanidipino, manidipino, nicardipino, nifedipino, nilvadipino, nimodipino, nisoldipino, nitrendipino, diltiazem, clentiazem, bepridilo, benciclano, etafenona, flunarizina, lidoflazina, lomerizina, mibefradilo, fendilina, prenilamina, semotiadilo, terodilina, galopamilo y verapamilo, dicho derivado de estatina se selecciona de entre el grupo que consiste en lovastatina, mevastatina, pravastatina y simvastatina.
Description
Claims (1)
-
imagen1 imagen2
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09425368 | 2009-09-23 | ||
| EP09425368 | 2009-09-23 | ||
| PCT/EP2010/062979 WO2011036047A1 (en) | 2009-09-23 | 2010-09-03 | Pharmaceutical composition for the treatment of mcp-1 mediated inflammatory diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2637024T3 true ES2637024T3 (es) | 2017-10-10 |
Family
ID=41722750
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES10747897.6T Active ES2637024T3 (es) | 2009-09-23 | 2010-09-03 | Composición farmacéutica para el tratamiento de enfermedades inflamatorias mediadas por MCP-1 |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US9492542B2 (es) |
| EP (1) | EP2480224B1 (es) |
| JP (2) | JP2013505278A (es) |
| KR (1) | KR101774402B1 (es) |
| CN (1) | CN102573827B (es) |
| AR (1) | AR078307A1 (es) |
| AU (1) | AU2010297405B2 (es) |
| BR (1) | BR112012006149A2 (es) |
| CA (1) | CA2760180C (es) |
| CY (1) | CY1119125T1 (es) |
| DK (1) | DK2480224T3 (es) |
| EA (1) | EA021485B1 (es) |
| ES (1) | ES2637024T3 (es) |
| GE (1) | GEP20146067B (es) |
| HR (1) | HRP20171209T1 (es) |
| HU (1) | HUE033102T2 (es) |
| IL (1) | IL218001A (es) |
| LT (1) | LT2480224T (es) |
| MX (1) | MX347957B (es) |
| PL (1) | PL2480224T3 (es) |
| PT (1) | PT2480224T (es) |
| SG (2) | SG10201405408YA (es) |
| SI (1) | SI2480224T1 (es) |
| SM (1) | SMT201700330T1 (es) |
| UA (1) | UA108742C2 (es) |
| WO (1) | WO2011036047A1 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101581829B1 (ko) | 2008-03-07 | 2015-12-31 | 아지엔드 키미쉐 리유나이트 안젤리니 프란체스코 에이.씨.알.에이.에프. 에스.피.에이 | 1-벤질-3-하이드록시메틸인다졸 유도체들 및 ｍｃｐ-1 및 ｃｘ3ｃｒ1의 발현을 기초로 한 질환들의 치료에서 이의 용도 |
| EP2262778B8 (en) | 2008-03-07 | 2020-01-01 | Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A. | 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cx3cr1 and p40 |
| US8999292B2 (en) | 2012-05-01 | 2015-04-07 | Translatum Medicus Inc. | Methods for treating and diagnosing blinding eye diseases |
| US11221321B2 (en) * | 2019-05-29 | 2022-01-11 | Imam Abdulrahman Bin Faisal University | Liquid chromatographic method for the simultaneous analysis of antihypertensive and antilipidemic agents and interactions thereof |
| EP3990433B1 (en) | 2019-06-25 | 2026-05-20 | Translatum Medicus Inc | PROCESSES FOR THE MANUFACTURE OF 2-((1-BENZYL-1H-INDAZOL-3-YL)METHOXY)-2-METHYLPROPANOIC ACID AND ITS DERIVATIVES |
| JP2023082437A (ja) * | 2021-12-02 | 2023-06-14 | 学校法人東京薬科大学 | Ｃｃｌ８による免疫細胞の動員が関与する炎症を抑制するための組成物 |
| CN116688135B (zh) * | 2023-07-28 | 2024-10-29 | 四川大学华西医院 | 一种骨关节炎药物治疗组合物及其制备方法和应用 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI88400C (fi) | 1984-08-06 | 1993-05-10 | Upjohn Co | Foerfarande foer framstaellning av renin inhiberande peptider |
| MY103189A (en) | 1986-10-31 | 1993-05-29 | Pfizer | Nor-statine and nor-cyclostatine polypeptides |
| US4927807A (en) | 1987-10-06 | 1990-05-22 | Abbott Laboratories | Glaucoma treatment |
| IT1230441B (it) * | 1989-02-07 | 1991-10-23 | Acraf | Eteri della serie dell'indazolo |
| CA2023099A1 (en) | 1989-09-04 | 1991-03-05 | Quirico Branca | Amino acid derivatives |
| US5209933A (en) | 1990-01-10 | 1993-05-11 | Syntex (U.S.A.) Inc. | Long acting calcium channel blocker composition |
| IE68045B1 (en) | 1990-05-11 | 1996-05-15 | Abbott Lab | Renin inhibitors |
| TW198712B (es) | 1991-04-17 | 1993-01-21 | Hoffmann La Roche | |
| IT1253703B (it) | 1991-04-22 | 1995-08-23 | Angelini Francesco Ist Ricerca | Uso di acidi metossi alcanoici dell'indazolo per preparare un farmaco attivo nel trattamento di malattie autoimmunitarie |
| MY119161A (en) | 1994-04-18 | 2005-04-30 | Novartis Ag | Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides with enzyme especially renin inhibiting activities |
| US5994348A (en) * | 1995-06-07 | 1999-11-30 | Sanofi | Pharmaceutical compositions containing irbesartan |
| IT1276031B1 (it) | 1995-10-31 | 1997-10-24 | Angelini Ricerche Spa | Composizione farmaceutica per il trattamento delle malattie autoimmuni |
| SE9600120D0 (sv) | 1996-01-15 | 1996-01-15 | Astra Ab | Novel medical use |
| IT1293795B1 (it) * | 1997-07-28 | 1999-03-10 | Angelini Ricerche Spa | Farmaco attivo nel ridurre la produzione di proteina mcp-1 |
| US6268377B1 (en) | 1998-09-28 | 2001-07-31 | Merck & Co., Inc. | Method for treating androgen-related conditions |
| GB0111077D0 (en) | 2001-05-04 | 2001-06-27 | Biochemie Gmbh | Organic compounds |
| JP2005501815A (ja) | 2001-05-14 | 2005-01-20 | メルク エンド カムパニー インコーポレーテッド | 治療方法 |
| US20030060502A1 (en) | 2001-09-19 | 2003-03-27 | Francois Mach | Treatment of diabetes with statins (HMG-COa reductase inhibitors) |
| US7183285B2 (en) | 2004-04-29 | 2007-02-27 | Pharmix Corp. | Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase |
| US20070060549A1 (en) | 2004-08-10 | 2007-03-15 | Friesen Albert D | Combination therapies employing ace inhibitors and uses thereof for the treatment of diabetic disorders |
| US20060046996A1 (en) | 2004-08-31 | 2006-03-02 | Kowa Co., Ltd. | Method for treating hyperlipidemia |
| EP1806137A4 (en) | 2004-10-29 | 2011-03-30 | Kowa Co | THERAPEUTIC AGENT FOR THE TREATMENT OF GLOMERULAR DISEASE |
| EP2526937A1 (en) | 2006-02-07 | 2012-11-28 | Mochida Pharmaceutical Co., Ltd. | Composition for prevention of recurrence of stroke |
| WO2008084504A2 (en) | 2007-01-12 | 2008-07-17 | Rubicon Research Private Limited | Pharmaceutical compositions of angiotensin ii receptor blockers |
| EP2481408A3 (en) * | 2007-03-01 | 2013-01-09 | Probiodrug AG | New use of glutaminyl cyclase inhibitors |
| EP2262778B8 (en) | 2008-03-07 | 2020-01-01 | Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A. | 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cx3cr1 and p40 |
| KR101581829B1 (ko) | 2008-03-07 | 2015-12-31 | 아지엔드 키미쉐 리유나이트 안젤리니 프란체스코 에이.씨.알.에이.에프. 에스.피.에이 | 1-벤질-3-하이드록시메틸인다졸 유도체들 및 ｍｃｐ-1 및 ｃｘ3ｃｒ1의 발현을 기초로 한 질환들의 치료에서 이의 용도 |
| KR101581828B1 (ko) * | 2008-03-07 | 2015-12-31 | 아지엔드 키미쉐 리유나이트 안젤리니 프란체스코 에이.씨.알.에이.에프. 에스.피.에이 | 신규한 1-벤질-3-하이드록시메틸인다졸 유도체들 및 ｍｃｐ-1, ｃｘ3ｃｒ1 및 ｐ40의 발현을 기초로 한 질환들의 치료에서 이의 용도 |
-
2010
- 2010-03-09 UA UAA201203482A patent/UA108742C2/uk unknown
- 2010-09-03 CN CN201080042390.9A patent/CN102573827B/zh not_active Expired - Fee Related
- 2010-09-03 EP EP10747897.6A patent/EP2480224B1/en active Active
- 2010-09-03 BR BR112012006149A patent/BR112012006149A2/pt not_active Application Discontinuation
- 2010-09-03 HU HUE10747897A patent/HUE033102T2/en unknown
- 2010-09-03 EA EA201270449A patent/EA021485B1/ru not_active IP Right Cessation
- 2010-09-03 JP JP2012530204A patent/JP2013505278A/ja active Pending
- 2010-09-03 SG SG10201405408YA patent/SG10201405408YA/en unknown
- 2010-09-03 CA CA2760180A patent/CA2760180C/en not_active Expired - Fee Related
- 2010-09-03 US US13/497,175 patent/US9492542B2/en not_active Expired - Fee Related
- 2010-09-03 SG SG2012010302A patent/SG178414A1/en unknown
- 2010-09-03 PL PL10747897T patent/PL2480224T3/pl unknown
- 2010-09-03 AU AU2010297405A patent/AU2010297405B2/en not_active Ceased
- 2010-09-03 KR KR1020127007411A patent/KR101774402B1/ko not_active Expired - Fee Related
- 2010-09-03 ES ES10747897.6T patent/ES2637024T3/es active Active
- 2010-09-03 SM SM20170330T patent/SMT201700330T1/it unknown
- 2010-09-03 WO PCT/EP2010/062979 patent/WO2011036047A1/en not_active Ceased
- 2010-09-03 MX MX2012003485A patent/MX347957B/es active IP Right Grant
- 2010-09-03 GE GEAP201012675A patent/GEP20146067B/en unknown
- 2010-09-03 HR HRP20171209TT patent/HRP20171209T1/hr unknown
- 2010-09-03 PT PT107478976T patent/PT2480224T/pt unknown
- 2010-09-03 SI SI201031512T patent/SI2480224T1/sl unknown
- 2010-09-03 DK DK10747897.6T patent/DK2480224T3/en active
- 2010-09-03 LT LTEP10747897.6T patent/LT2480224T/lt unknown
- 2010-09-22 AR ARP100103447A patent/AR078307A1/es unknown
-
2012
- 2012-02-09 IL IL218001A patent/IL218001A/en not_active IP Right Cessation
-
2015
- 2015-07-31 JP JP2015152596A patent/JP6122470B2/ja active Active
-
2017
- 2017-07-28 CY CY20171100808T patent/CY1119125T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2014111474A (ru) | Способы лечения сердечно-сосудистых нарушений | |
| HRP20171209T1 (hr) | Farmaceutski pripravak za liječenje upalnih bolesti posredovanih putem mcp-1 | |
| ME01614B (me) | Farmaceutska kompozicija snažnog hcv inhibitora za oralnu primjenu | |
| NZ595073A (en) | Proline derivatives as cathepsin inhibitors | |
| ZA200810023B (en) | Phosphoinositide 3-kinase inhibitor compounds and pharmaceutical compositions containing them | |
| IL193839A (en) | N-hydroxylsulfonamide history as new physiologically useful nitroxyl donors | |
| RU2006106451A (ru) | Сложноэфирные соединения и их применение в медицине | |
| CA2514921A1 (en) | Combined use of olmesartan medoxomil and azelnidipine or amlodipine for the treatment of arteriosclerosis and hypertension | |
| CL2011002662A1 (es) | Preparacion solida que comprende i) acido y ester de 2 - etoxi- 1 - (ciclohexiloxicarboniloxi)etil-2-etoxi-1-[[2-(1h-tetrazol- 5- il) bifenil-4-il]bifenil-4-]metil]bencimidazol-7-carboxilico, acido y 2-etoxi- 1-[[2-(4,5-dihidro-5-oxo-1,2,4-oxadiazol-3-il)bifenil-4-il]metil]-1h-bencimidazol-7- carboxilico, ii) manitol, y iii) amlodipino. | |
| LT2313087T (lt) | Farmacinė vaisto forma, skirta indolinono darinio greitam atpalaidavimui | |
| MX2011012199A (es) | Derivados de benzoxazolona como inhibidores de la sintasa de aldosterona. | |
| RU2019126749A (ru) | Композиции для лечения гипертензии | |
| PE20080175A1 (es) | Sales de malato, y polimorfos de acido (3s,5s)-7-[3-amino-5-metil-piperidinil]-1-ciclopropil-1,4-dihidro-8-metoxi-4-oxo-3-quinolincarboxilico | |
| FR2925331B1 (fr) | Utilisation d'un hydrolysat de feve en tant que principe actif activateur de la synthese des aquaporines | |
| FR2954311B1 (fr) | Procede de synthese perfectionne d'acroleine a partir de glycerol | |
| RU2011124739A (ru) | Композиции, содержащие ингибиторы системы ренин-ангиотензин альдостерона и соединения липоевой кислоты, и их применение для лечения заболеваний, связанных с системой ренин-ангиотензин альдостерона | |
| NZ599268A (en) | Pharmaceutical compositions of rhein or diacerein made by wet granulation process | |
| FR2930936B1 (fr) | Systeme de regulation d'un portique a double moyen d'entrainement | |
| EP2657336A4 (en) | BIOASSAY PROCEDURE FOR DETECTING A PHYSIOLOGICALLY ACTIVE SUBSTANCE | |
| IL210141A0 (en) | Pharmaceutical composition comprising n-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3h-indol-3-ylidene)methyl]-2,4-dimethyl-1 h-pyrrole-3-carboxamide | |
| FR2925490B1 (fr) | Procede de synthese d'acroleine a partir de glycerol | |
| PE20090675A1 (es) | Composicion farmaceutica que contie levosimendan y un antagonista receptor de angiotensina ii o un inhibidor eca | |
| PE20130241A1 (es) | Agente terapeutico de liberacion sostenida para la hipertension y la disfuncion renal | |
| MY160597A (en) | Salts of isobutyric acid (1r*, 2r*, 4r*) -2- (2-{ [3- (4, 7-dimethoxy-1 h-benzoimidazol-2-yl) -methyl-amino } -ethyl) -5-phenyl-bicyclo [2.2.2] oct-5-en-2-yl ester | |
| MY143949A (en) | An orally active thrombin inhibitor |